GlassScriptPhysician profile
Joseph Haddad
NPI 1952447351
$3,650.00
in general payments reported to CMS, 2019-2025
26 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $122 · 2021: $421 · 2022: $604 · 2023: $582 · 2024: $786 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $608.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $548.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $446.31 | 2019-2025 | |
| Kaleo, INC. | $364.31 | 2022-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $221.73 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Teva Pharmaceuticals USA, INC. | $175.67 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $168.58 | 2022-2024 | |
| Hikma Pharmaceuticals USA | $129.90 | 2023-2024 | Ryaltris |
| Acclarent, INC | $115.38 | 2021 | |
| Grifols USA, LLC | $113.70 | 2025 | Xembify |
| Amgen INC. | $106.97 | 2022-2024 | Tezspire |
| Stryker Corporation | $87.57 | 2022-2025 | Scopis Ent |
| Alk-Abello, INC | $84.34 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Astrazeneca Pharmaceuticals LP | $70.66 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $65.17 | 2023-2024 | Orladeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $49.86 | 2019-2020 | |
| Ionis Pharmaceuticals, INC. | $48.67 | 2025 | Dawnzera |
| Medtronic, INC. | $45.73 | 2023-2025 | Propel, Sinuva |
| Blueprint Medicines Corporation | $41.57 | 2024 | Ayvakit |
| Csl Behring | $32.82 | 2025 | Hizentra |
| Inspire Medical Systems, INC. | $29.22 | 2025 | Inspire |
| Pfizer INC. | $24.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.43 | 2019 | |
| Phadia US INC. | $18.40 | 2024 | Immunocap |
| Shire North American Group INC | $17.26 | 2019 | |
| Smith+Nephew, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.